Skip to main content
  • Saved

Small interfering RNA to proprotein convertase... : Current Opinion in Lipidology

Small interfering RNA to proprotein convertase... : Current Opinion in Lipidology

Source : https://journals.lww.com/co-lipidology/Abstract/9000/Small_interfering_RNA_to_proprotein_convertase.99318.aspx

ll interfering RNA developed for this purpose is inclisiran. Here, we review its clinical trial data and potential impact on patient management. Recent findings Inclisiran achieves sustained, additional 50% LDL-C reduction in patients receiving background statin therapy. Resulting LDL-C changes can be maintained by an infrequent dosing regimen with twice per year injections, that appear safe and well tolerated.